ANTI-SKI

The Uses of ANTI-SKI

The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 1:50. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.

The Uses of ANTI-SKI

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .

General Description

The antibody SIT-01 reacts with SHP2-interacting transmembrane adaptor protein (SIT) expressed exclusively in lymphoid organs. It weakly crossreacts with mouse SIT.

Biochem/physiol Actions

SIT1 (Signaling threshold-regulating transmembrane adapter-1) inhibits T-cell receptor signaling and T-cell receptor-mediated phosphorylation of AKT (RAC-γ serine/threonine-protein kinase). Down-regulation of SIT1 promotes T-cell receptor-mediated AKT (RAC-α serine/threonine-protein kinase) activation and causes inactivation of FOXO1 (Forkhead box protein O1), a transcription factor that inhibits cell cycle progression and regulates T-cell homeostasis. SIT1 is involved in positive selection of T-cells. It regulates the signals required for thymic selection and peripheral T-cell activation.